TrialHaematologica2018

Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma).

Johannes M Waldschmidt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.